- Home
- ENIC vs NUVL Comparison
ENIC vs NUVL Comparison
Compare ENIC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENIC
- NUVL
- Stock Information
- Founded
- ENIC 2016
- NUVL 2017
- Country
- ENIC Chile
- NUVL United States
- Employees
- ENIC N/A
- NUVL N/A
- Industry
- ENIC Electric Utilities: Central
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ENIC Utilities
- NUVL Health Care
- Exchange
- ENIC Nasdaq
- NUVL Nasdaq
- Market Cap
- ENIC 5.1B
- NUVL 5.8B
- IPO Year
- ENIC N/A
- NUVL 2021
- Fundamental
- Price
- ENIC $3.73
- NUVL $81.16
- Analyst Decision
- ENIC Hold
- NUVL Strong Buy
- Analyst Count
- ENIC 2
- NUVL 11
- Target Price
- ENIC $3.90
- NUVL $120.91
- AVG Volume (30 Days)
- ENIC 505.9K
- NUVL 397.5K
- Earning Date
- ENIC 10-28-2025
- NUVL 11-11-2025
- Dividend Yield
- ENIC 5.00%
- NUVL N/A
- EPS Growth
- ENIC N/A
- NUVL N/A
- EPS
- ENIC 0.00
- NUVL N/A
- Revenue
- ENIC $4,040,237,917.00
- NUVL N/A
- Revenue This Year
- ENIC $111,648.61
- NUVL N/A
- Revenue Next Year
- ENIC N/A
- NUVL N/A
- P/E Ratio
- ENIC $37.28
- NUVL N/A
- Revenue Growth
- ENIC N/A
- NUVL N/A
- 52 Week Low
- ENIC $2.53
- NUVL $55.54
- 52 Week High
- ENIC $4.05
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ENIC 67.20
- NUVL 58.20
- Support Level
- ENIC $3.59
- NUVL $74.40
- Resistance Level
- ENIC $3.75
- NUVL $83.09
- Average True Range (ATR)
- ENIC 0.08
- NUVL 2.98
- MACD
- ENIC 0.02
- NUVL 0.60
- Stochastic Oscillator
- ENIC 92.86
- NUVL 77.78
About ENIC Enel Chile S.A. (Each representing 50 shares of)
Enel Chile SA is an electricity utility company, which through its subsidiaries and affiliates is engaged in the generation, transmission and distribution of electricity businesses in Chile. It operates through two segments including Generation Business and Distribution and Network Business. The Generation Business Segment is comprised of a group of electricity companies that own electricity generating plants, whose energy is transmitted and distributed to end customers. The Distribution and Network Reportable Segment is comprised of a group of electricity companies operating under a public utility concession.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.